RT @synovialjoints: The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected…
Tweet Content
The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected safety findings. IXE superior to PBO for improving signs, symptoms, and inflammation on MRI in pts with nr-axSpA abstract #2729 #ACR19 @RheumNow
Show on Archive Page
On
Display in Search Results
On